Making BREAKTHROUGH DISCOVERIES a reality.
Advancing scientific discovery
Passionate about equipping researchers with next-generation technology, inspiring innovative solutions that advance scientific discovery, to improve the quality of human life worldwide.
A life science company
Four decades dedicated to enabling life science labs of the future, where innovative technology and novel research converge.

State-of-the-art automated 3D imaging workcell
The Organoid Innovation Center at Molecular Devices combines cutting-edge technologies with novel research methods to address key challenges of scaling complex 3D biological models.
The collaborative space brings customers and researchers into the lab to test automated workflows for organoid culturing and screening, with guidance from in-house scientists.
3D Biology
3D biology is an emerging field revolutionizing the way scientists screen new drugs and understand diseases.
3D cell models like organoids have a unique makeup that offers a step-change in predicting human responses to novel treatments. Their increased physiological relevance leads to more accurate indications of a therapeutic’s efficacy in the pre-clinical phase. This allows for the weeding out of toxic, ineffective compounds to make space for those with healing power earlier in the drug discovery process.
Cell Engineering
The addition of our colony picker platform expands the Center’s state-of-the-art methods and technologies to include automated workflows for synthetic biology, antibody discovery, and cell line development.
And, with the recent launch of CloneSelect® Imager FL with multi-channel fluorescence for day zero monoclonality verification and confirmation of CRISPR edits, provides a wide range of cell and gene therapy applications.
Lab Automation
From our PhD-level technical support staff to our expert-trained and certified field service engineers, our Global Professional Services teams guide scientists through customized automation solutions that are uniquely designed to meet the specific needs of your assay, method, or protocol.
We offer a highly consultative approach when automating high-throughput plate-based, cellular screening, and clone screening assays with customized, automated labware, robotic solutions, and intuitive software.
Proprietary patient-derived organoid technology
“Molecular Devices has the capability, reputation, reach, and resources to ensure that the Cellesce technology can be further developed, and used to its full potential. We’re excited to bring our domain expertise and intellectual property to Molecular Devices, together maximizing impact for customers in revolutionizing drug discovery and unlocking the full potential of human-relevant 3D biology research.”
– Vicky Marsh-Durban,
CEO of Cellesce
We empower scientists to advance discovery
Automated, end-to-end solutions span research disciplines to help scientists discover, scale, and industrialize biology.

SpectraMax® Microplate Readers and SoftMax® Pro Software
For nearly 40 years, we have partnered with scientists to help them achieve landmark discoveries. Our microplate readers and software are the industry’s most cited and have empowered life science researchers to advance protein and cell biology.

New multi-mode microplate reader for academia and biotech laboratories
The budget-friendly SpectraMax® Mini Multi-Mode Microplate Reader maximizes productivity without compromising sensitivity or performance. A compact and economical solution designed to save researchers benchtop space and budget.

GxP Compliance Solutions
A leader in comprehensive GxP compliance solutions, we combine our SpectraMax® microplate readers, SoftMax® Pro GxP software, SpectraTest® Validation Plates and expert IQ/OQ/PM services to help laboratories operating under GMP and GLP regulations follow FDA or regional regulatory guidelines with confidence.

Next-gen ImageXpress® High-content Imaging System with AI Technology
The ImageXpress® Confocal HT.ai High-Content Imaging System combines premium hardware technology with IN Carta Image Analysis Software, a self-learning software analysis workflow for increased signal and ultra-fast 3D organoid screening.

Automated, turnkey platform with BioAssemblyBot® 400 bioprinting technology
Out-of-the-box integration of the enhanced BAB400 for Drug Discovery with ImageXpress® cellular imaging system enables turnkey automation of cell health monitoring and end-point assays.

Automated solutions for high-throughput, high-content screening
Our automated, high-content screening workcell provides an end-to-end solution that helps standardize live 2D/3D cellular development process with cell culture, treatment, and incubation, through to imaging, analysis, and data processing, delivering consistent, unbiased, and biologically-relevant results at scale.

Clone screening systems for colony picking and single-cell isolation
The QPix® 400 Microbial Colony Picker, ClonePix® 2 Mammalian Colony Picker, and CloneSelect® FL Imager increase throughput and consistency across cell line development, monoclonal antibody discovery, and synthetic biology workflows.

DispenCell Single-Cell Dispenser technology isolates single cell lines 3x faster and at lower cost
Molecular Devices is now an exclusive commercial supplier of the award-winning DispenCell™ Single-Cell Dispenser – an automated laboratory instrument designed for fast, easy, and gentle single-cell isolation for proof of monoclonality.

CloneSelect® Imager FL platform for day zero monoclonality assurance
The CSI FL is capable of imaging and reporting on label-free and multiplexed gene-edited single cells with automated monoclonal verification reporting.

Automated solutions for high-throughput clone screening
Fully-integrated, lab automation solution for molecular cloning, antibody discovery, and monoclonality. Our automated clone screening workflows integrate laboratory devices to increase your throughput and efficiency while reducing human interaction.
We’re scientists supporting scientists
We empower scientists to advance discovery, driving earlier diagnoses and safer therapeutics for patients.

3D Biology: The paradigm shift in next-gen drug discovery
In the midst of an evolving drug discovery paradigm, researchers worldwide are transitioning their compound screens away from 2D cell cultures and animal models to more complex, human-relevant 3D systems like organoids. Experience our interactive infographic as it takes you deeper into why the industry is embracing this next generation of drug discovery and the innovations supporting scientists in their 3D biology journey.
Drug Discovery & Development
The drug discovery landscape is shifting, with more scientists centering cell line development, disease models, and high-throughput screening methods around physiologically-relevant 3D cell models.
The reason for this is clear: Using cellular model systems in research that closely mimic patient disease states or human organs can bring life-saving therapeutics to market – faster.
With our automated 3D cell culture and bioimaging screening solutions, we are helping reshape the future of drug discovery. Supported by our technology and organoid development protocols, researchers can now advance and scale screening methods for physiologically-relevant 3D models that more closely mimic patient disease states and human organs, leading to faster drug development and approval.
Cell Line Development
Our cell line development customers accelerate time to market for life saving monoclonal antibodies (mAbs) and genomic medicine, as well as perform groundbreaking research in cell and gene therapies, genetic engineering, personalized and precision medicine, synthetic biology, RNA and DNA-based vaccines, and so much more – made possible by our innovative technology and rich expertise.
Drug Screening
For every drug that makes it to the finish line, another nine don’t succeed. This alarming failure rate can be traced to reliance on 2D cell cultures that don’t closely mimic complex human biology, often leading to inaccurate predictions of a drug’s potential and extended drug development timelines.
A critical step in the drug discovery process, drug screening and toxicity assessment uncovers effects of potentially life-saving compounds. Scale drug discovery research with a high-throughput screening solution.